1-20 of 53
S. Gail Eckhardt
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer

Open Access
Robert W. Lentz, Tyler J. Friedrich, Patrick J. Blatchford, Kimberly R. Jordan, Todd M. Pitts, Hannah R. Robinson, S. Lindsey Davis, Sunnie S. Kim, Alexis D. Leal, Mathew R. Lee, Meredith R.N. Waring, Anne C. Martin, Adrian T.A. Dominguez, Stacey M. Bagby, Sarah J. Hartman, S. Gail Eckhardt, Wells A. Messersmith, Christopher H. Lieu
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (17): 3768–3778.
https://doi.org/10.1158/1078-0432.CCR-24-0090
Published: 03 September 2024
View articletitled, A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer
Open the PDF for A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study

Available to Purchase
John W. Moroney, John Powderly, Christopher H. Lieu, Johanna C. Bendell, S. Gail Eckhardt, Ching-Wei Chang, Luciana Molinero, Jessica Spahn, Patrick Williams, Yvonne G. Lin, F. Stephen Hodi
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (21): 5631–5637.
https://doi.org/10.1158/1078-0432.CCR-20-0477
Published: 02 November 2020
View articletitled, Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study
Open the PDF for Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study in another window
Journal Articles

Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors

Available to Purchase
S. Lindsey Davis, Anastasia A. Ionkina, Stacey M. Bagby, James D. Orth, Brian Gittleman, Joshua M. Marcus, Elaine T. Lam, Bradley R. Corr, Cindy L. O'Bryant, Ashley E. Glode, Aik-Choon Tan, Jihye Kim, John J. Tentler, Anna Capasso, Kyrie L. Lopez, Daniel L. Gustafson, Wells A. Messersmith, Stephen Leong, S. Gail Eckhardt, Todd M. Pitts, Jennifer R. Diamond
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (17): 4633–4642.
https://doi.org/10.1158/1078-0432.CCR-19-3498
Published: 01 September 2020
View articletitled, Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors
Open the PDF for Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer

Free
Christopher H. Lieu, Erica A. Golemis, Ilya G. Serebriiskii, Justin Newberg, Amanda Hemmerich, Caitlin Connelly, Wells A. Messersmith, Cathy Eng, S. Gail Eckhardt, Garrett Frampton, Matthew Cooke, Joshua E. Meyer
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (19): 5852–5858.
https://doi.org/10.1158/1078-0432.CCR-19-0899
Published: 01 October 2019
View articletitled, Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer
Open the PDF for Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract PR03: Characterizing the immune context of responses to immunotherapy in humanized patient derived xenograft models of CRC

Free
Anna Capasso, Julie Lang, Todd M. Pitts, S. Lindsey Davis, Chris H. Lieu, Stacey M. Bagby, Aik Choon Tan, John J. Tentler, Jill E. Slansky, Roberta Pelanda, S. Gail Eckhardt
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (16_Supplement): PR03.
https://doi.org/10.1158/1557-3265.PDX16-PR03
Published: 15 August 2016
View articletitled, Abstract PR03: Characterizing the immune context of responses to immunotherapy in humanized patient derived xenograft models of CRC
Journal Articles

Abstract IA20: Challenges, opportunities, and lessons learned in the bench-to-bedside translation of xenopatient studies

Free
S. Gail Eckhardt, Todd Pitts, Aik Choon Tan, Stacey Bagby, John Arcaroli, Anna Capasso, Kit Wong, Peter Klauck, Wells Messersmith, S Lindsey Davis, Christopher Lieu, Stephen Leong, Jennifer Diamond, John Tentler
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (16_Supplement): IA20.
https://doi.org/10.1158/1557-3265.PDX16-IA20
Published: 15 August 2016
View articletitled, Abstract IA20: Challenges, opportunities, and lessons learned in the bench-to-bedside translation of xenopatient studies
Journal Articles

Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors

Free
Valentine M. Macaulay, Mark R. Middleton, S. Gail Eckhardt, Charles M. Rudin, Rosalyn A. Juergens, Richard Gedrich, Sven Gogov, Sean McCarthy, Srinivasu Poondru, Andrew W. Stephens, Shirish M. Gadgeel
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (12): 2897–2907.
https://doi.org/10.1158/1078-0432.CCR-15-2218
Published: 14 June 2016
View articletitled, Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors
Open the PDF for Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors in another window
Journal Articles

Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors

Free
Jonathan Goldman, S. Gail Eckhardt, Mitesh J. Borad, Kelly K. Curtis, Manuel Hidalgo, Emiliano Calvo, David P. Ryan, Lori J. Wirth, Asit Parikh, James Partyka, Helene Faessel, Esha Gangolli, Sally Stewart, Lee S. Rosen, Daniel W. Bowles
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (5): 1002–1009.
https://doi.org/10.1158/1078-0432.CCR-14-1234
Published: 01 March 2015
View articletitled, Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors
Open the PDF for Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies

Free
Daniel W. Bowles, Jennifer R. Diamond, Elaine T. Lam, Colin D. Weekes, David P. Astling, Ryan T. Anderson, Stephen Leong, Lia Gore, Marileila Varella-Garcia, Brian W. Vogler, Stephen B. Keysar, Elizabeth Freas, Dara L. Aisner, Chen Ren, Aik-Chook Tan, Francois Wilhelm, Manoj Maniar, S. Gail Eckhardt, Wells A. Messersmith, Antonio Jimeno
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (6): 1656–1665.
https://doi.org/10.1158/1078-0432.CCR-13-2506
Published: 13 March 2014
View articletitled, Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies
Open the PDF for Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies in another window
Includes: Supplementary data
Journal Articles

Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models

Free
Sara A. Flanigan, Todd M. Pitts, Timothy P. Newton, Gillian N. Kulikowski, Aik Choon Tan, Martine C. McManus, Anna Spreafico, Maria I. Kachaeva, Heather M. Selby, John J. Tentler, S. Gail Eckhardt, Stephen Leong
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (22): 6219–6229.
https://doi.org/10.1158/1078-0432.CCR-13-0145
Published: 14 November 2013
View articletitled, Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models
Open the PDF for Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models in another window
Includes: Supplementary data
Journal Articles

Accelerated Approval and Breakthrough Therapy Designation: Oncology Drug Development on Speed?

Free
James C. Yao, Funda Meric-Bernstam, J. Jack Lee, S. Gail Eckhardt
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (16): 4305–4308.
https://doi.org/10.1158/1078-0432.CCR-13-1428
Published: 13 August 2013
View articletitled, Accelerated Approval and Breakthrough Therapy Designation: Oncology Drug Development on Speed?
Open the PDF for Accelerated Approval and Breakthrough Therapy Designation: Oncology Drug Development on Speed? in another window
Includes: Supplementary data
Journal Articles

Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer

Free
Anna Spreafico, John J. Tentler, Todd M. Pitts, Aik Choon Tan, Mark A. Gregory, John J. Arcaroli, Peter J. Klauck, Martine C. McManus, Ryan J. Hansen, Jihye Kim, Lindsey N. Micel, Heather M. Selby, Timothy P. Newton, Kelly L. McPhillips, Daniel L. Gustafson, James V. DeGregori, Wells A. Messersmith, Robert A. Winn, S. Gail Eckhardt
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (15): 4149–4162.
https://doi.org/10.1158/1078-0432.CCR-12-3140
Published: 31 July 2013
View articletitled, Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer
Open the PDF for Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract A46: Tumor P-glycoprotein Correlates with Efficacy of PF-03758309 Against In Vitro and In Vivo models of Colorectal Cancer

Free
Erica L. Bradshaw-Pierce, Todd M. Pitts, Kelly L. McPhillips, Daniel L. Gustafson, Aik-Choon Tan, Leslie Nguyen, Mark West, Timothy Fisher, Brion W. Murray, S. Gail Eckhardt
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10_Supplement): A46.
https://doi.org/10.1158/1078-0432.MECHRES-A46
Published: 04 March 2013
View articletitled, Abstract A46: Tumor P-glycoprotein Correlates with Efficacy of PF-03758309 Against In Vitro and In Vivo models of Colorectal Cancer
Open the PDF for Abstract A46: Tumor P-glycoprotein Correlates with Efficacy of PF-03758309 Against In Vitro and In Vivo models of Colorectal Cancer in another window
Journal Articles

Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer

Free
Colin D. Weekes, Daniel D. Von Hoff, Alex A. Adjei, Diane P. Leffingwell, S. Gail Eckhardt, Lia Gore, Karl D. Lewis, Glen J. Weiss, Ramesh K. Ramanathan, Grace K. Dy, Wen W. Ma, Beth Sheedy, Cory Iverson, Jeffrey N. Miner, Zancong Shen, Li-Tain Yeh, Ronald L. Dubowy, Michael Jeffers, Prabhu Rajagopalan, Neil J. Clendeninn
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (5): 1232–1243.
https://doi.org/10.1158/1078-0432.CCR-12-3529
Published: 03 March 2013
View articletitled, Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer
Open the PDF for Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer in another window
Includes: Supplementary data
Journal Articles

First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies

Free
Timothy A. Yap, Hendrik-Tobias Arkenau, D. Ross Camidge, Suzanne George, Natalie J. Serkova, Stephen J. Gwyther, Jennifer L. Spratlin, Rohit Lal, James Spicer, Nandita M. Desouza, Martin O. Leach, Jon Chick, Srinivasu Poondru, Ramesh Boinpally, Richard Gedrich, Katie Brock, Andrew Stephens, S. Gail Eckhardt, Stan B. Kaye, George Demetri, Michelle Scurr
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (4): 909–919.
https://doi.org/10.1158/1078-0432.CCR-12-2258
Published: 14 February 2013
View articletitled, First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies
Open the PDF for First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies in another window
Includes: Supplementary data
Journal Articles

Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models

Free
Jennifer R. Diamond, S. Gail Eckhardt, Aik Choon Tan, Timothy P. Newton, Heather M. Selby, Kelsey L. Brunkow, Maria I. Kachaeva, Marileila Varella-Garcia, Todd M. Pitts, Mark R. Bray, Graham C. Fletcher, John J. Tentler
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (1): 291–303.
https://doi.org/10.1158/1078-0432.CCR-12-1611
Published: 02 January 2013
View articletitled, Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models
Open the PDF for Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models in another window
Includes: Supplementary data
Journal Articles

A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors

Free
David S. Hong, Daniel W. Bowles, Gerald S. Falchook, Wells A. Messersmith, Goldy C. George, Cindy L. O'Bryant, Alex C. H. Vo, Kevin Klucher, Roy S. Herbst, S. Gail Eckhardt, Scott Peterson, Diana F. Hausman, Razelle Kurzrock, Antonio Jimeno
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (15): 4173–4182.
https://doi.org/10.1158/1078-0432.CCR-12-0714
Published: 30 July 2012
View articletitled, A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors
Open the PDF for A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Common PIK3CA Mutants and a Novel 3′ UTR Mutation Are Associated with Increased Sensitivity to Saracatinib

Free
John J. Arcaroli, Kevin S. Quackenbush, Rebecca W. Powell, Todd M. Pitts, Anna Spreafico, Marileila Varella-Garcia, Lynne Bemis, Aik Choon Tan, Jaclyn M. Reinemann, Basel M. Touban, Arvind Dasari, S. Gail Eckhardt, Wells A. Messersmith
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (9): 2704–2714.
https://doi.org/10.1158/1078-0432.CCR-11-3167
Published: 30 April 2012
View articletitled, Common PIK3CA Mutants and a Novel 3′ UTR Mutation Are Associated with Increased Sensitivity to Saracatinib
Open the PDF for Common PIK3CA Mutants and a Novel 3′ UTR Mutation Are Associated with Increased Sensitivity to Saracatinib in another window
Includes: Supplementary data
Journal Articles

Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer

Free
Wen Wee Ma, Wells A. Messersmith, Grace K. Dy, Colin D. Weekes, Amy Whitworth, Chen Ren, Manoj Maniar, Francois Wilhelm, S. Gail Eckhardt, Alex A. Adjei, Antonio Jimeno
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (7): 2048–2055.
https://doi.org/10.1158/1078-0432.CCR-11-2813
Published: 01 April 2012
View articletitled, Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer
Open the PDF for Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination with Vorinostat in KRAS-Mutant Colorectal Cancer Models

Free
M. Pia Morelli, John J. Tentler, Gillian N. Kulikowski, Aik-Choon Tan, Erica L. Bradshaw-Pierce, Todd M. Pitts, Amy M. Brown, Sujatha Nallapareddy, John J. Arcaroli, Natalie J. Serkova, Manuel Hidalgo, Fortunato Ciardiello, S. Gail Eckhardt
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (4): 1051–1062.
https://doi.org/10.1158/1078-0432.CCR-11-1507
Published: 14 February 2012
View articletitled, Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination with Vorinostat in KRAS-Mutant Colorectal Cancer Models
Open the PDF for Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination with Vorinostat in KRAS-Mutant Colorectal Cancer Models in another window
Includes: Supplementary data